Telesis Bio Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD; shares in millions, except per-share amounts

	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021	Q2 FY2021 As of Jun 30, 2021
Assets
Current assets:
Cash and cash equivalents
Restricted cash
Short-term investments
Accounts receivable, net of allowance for credit losses of $320 and $1,197 at September 30, 2024 and December 31, 2023, respectively
Inventory, net
Prepaid expenses and other current assets
Assets of discontinued operations
Total current assets
Property and equipment, net
Right-of-use assets
Other long-term assets
Goodwill
Other intangible assets, net
Noncurrent assets of discontinued operations
Total assets
Liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity
Current liabilities:
Accounts payable
Accrued employee expenses
Finance lease liability, current portion
Operating lease liability, current portion
Notes payable, current portion
Derivative liabilities
Deferred revenue, current portion
Other accrued liabilities
Other current liabilities
Current liabilities of discontinued operations
Total current liabilities

Finance lease liability, net of current portion
Operating lease liability, net of current portion
Notes payable, net of discount
Related Party
Total notes payable, net of discount
Derivative liabilities
Deferred revenue, net of current portion
Noncurrent liabilities of discontinued operations
Total liabilities
Redeemable convertible preferred stock, 280,000 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively; liquidation preference of $31,096 and $29,300 at September 30, 2024 and December 31, 2023, respectively
Series Z Convertible Preferred Stock
Series A Convertible Preferred Stock
Series A-1 Convertible Preferred Stock
Total redeemable convertible preferred stock, 280,000 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively; liquidation preference of $31,096 and $29,300 at September 30, 2024 and December 31, 2023, respectively
Stockholders' (deficit) equity
Preferred stock, $.0001 par value; 5,000,000 shares authorized at March 31, 2023 and December 31, 2022. No shares issued and outstanding
Common stock, $0.0001 par value; 100,000,000 shares authorized at September 30, 2024 and December 31, 2023; 1,771,578 and 1,670,185 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders' (deficit) equity
Total liabilities, redeemable convertible preferred stock and stockholders' (deficit) equity
Common stock, shares authorized (in shares)

Comments